Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ February 4, 2023 ] senior Associate I, Technical Services – Kite Pharma – El Segundo, CA Los Angeles Biotech Jobs
  • [ February 4, 2023 ] Quality Assurance Specialist III – NKGen Biotech – Santa Ana, CA Los Angeles Biotech Jobs
  • [ February 4, 2023 ] Engineer I/II (Pharma Operations) – Glaukos Corporation – San Clemente, CA Los Angeles Biotech Jobs
  • [ February 4, 2023 ] First Look at Data on Biosense Webster’s Investigational Pulsed Field Ablation Platform Presented at AF Symposium 2023 Los Angeles Biotech News
  • [ February 4, 2023 ] Age-related macular degeneration (AMD) market size to increase by USD 4,360.68 million: Evolving Opportunities with Amgen Inc and Apellis Pharmaceuticals Inc among others – Technavio Los Angeles Biotech News
HomeLos Angeles Biotech NewsMirati’s KRAS-blocking cancer drug approved by FDA

Mirati’s KRAS-blocking cancer drug approved by FDA

December 13, 2022 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Mirati’s KRAS-blocking cancer drug approved by FDA

Cleared for a certain kind of mutated lung cancer, the medicine will challenge Amgen’s similarly acting treatment Lumakras.

Click to view original post

Previous

Postdoctoral Scholar or Career Track Research Scientist (Human Genetics; Charleston Chiang Lab) – Los Angeles, CA

Next

Specialty Diagnostics Technology and Solutions Provider Unveils New Brand Identity as SmartHealth Diagnostics

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered